ENLV - CIK 0001596812
The table below shows Enlivex Therapeutics Ltd.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.20M | $10.62M | $19.01M | $18.69M | $12.88M | $6.09M |
| SG&A | $5.80M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.91M |
| $6.14M |
| $7.10M |
| $6.41M |
| $3.70M |
| Operating income | -$15.03M | -$15.89M | -$29.39M | -$25.80M | -$19.29M | -$9.79M |
| Income tax | $382.65M | - | - | - | - | - |
| Net income | $1.24B | -$15.01M | -$29.07M | -$31.06M | -$14.47M | -$11.82M |
| EPS (diluted) | $25.48 | -$0.73 | -$1.56 | -$1.69 | -$0.81 | -$0.90 |